Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel
NYSE:ANRO

Alto Neuroscience Q2 2026 Earnings Report

Alto Neuroscience logo
$26.89 +0.99 (+3.82%)
Closing price 03:59 PM Eastern
Extended Trading
$27.08 +0.20 (+0.73%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Alto Neuroscience EPS Results

Actual EPS
N/A
Consensus EPS
-$0.71
Beat/Miss
N/A
One Year Ago EPS
N/A

Alto Neuroscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alto Neuroscience Announcement Details

Quarter
Q2 2026
Date
8/12/2026
Time
Before Market Opens
Conference Call Date
Friday, August 14, 2026
Conference Call Time
12:30PM ET

Conference Call Resources

Alto Neuroscience Earnings Headlines

Alto Neuroscience (NYSE:ANRO) Upgraded at Wall Street Zen
July 18 at 1:07 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30905235
ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm
July 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20241022183309/en/ANRO-Investors-Have-Opportunity-to-Join-Alto-Neuroscience-Inc.-Fraud-Investigation-with-the-Schall-Law-Firm
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
July 21 at 1:00 AM  |  Altimetry (Ad)
ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm
July 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20241022183309/en/ANRO-Investors-Have-Opportunity-to-Join-Alto-Neuroscience-Inc.-Fraud-Investigation-with-the-Schall-Law-Firm
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
July 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260713672035/en/alto-neuroscience-announces-pricing-of-100.0-million-underwritten-registered-direct-offering-of-common-stock/
Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment?
July 2, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/is-alto-neuroscience-inc-anro-stock-positioned-for-growth-with-new-insights-into-anhedonia-treatment-1793957/
See More Alto Neuroscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alto Neuroscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alto Neuroscience and other key companies, straight to your email.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies. By partnering with biopharmaceutical companies and academic institutions, the company seeks to de-risk clinical trials, reduce time to market and enhance go-to-market strategies for novel psychiatric medications. Ongoing collaborations focus on validating biomarkers and expanding the platform’s utility across multiple neuropsychiatric indications.

Formed in the late 2010s and headquartered in New York, Alto Neuroscience has assembled a leadership team with deep expertise in neuroscience, drug development and data analytics. Under the direction of co-founder and Chief Executive Officer Marshall Brennan, the company has initiated multiple clinical programs in the United States and Europe. Alto continues to expand its global footprint through strategic partnerships and joint research agreements.

As a publicly traded company on the New York Stock Exchange, Alto Neuroscience is positioned at the intersection of digital health and psychiatry. Its mission is to transform the standard of care for neuropsychiatric patients by delivering predictive tools that enable more personalized, effective treatments.

View Alto Neuroscience Profile
Earnings Tools